Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer

@inproceedings{Gomez2018IntegrativePA,
  title={Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer},
  author={Daniel Richard Gomez and Lauren A. Byers and Monique B Nilsson and Lixia Diao and Jing Wang and Lerong Li and Pan Tong and Mia Hofstad and Babita Saigal and Ignacio Wistuba and Neda Kalhor and Stephen G Swisher and Youhong Fan and Waun Ki Hong and Milind B. Suraokar and Carmen Behrens and C{\'e}sar A. Moran and John V. Heymach},
  booktitle={Oncotarget},
  year={2018}
}
While several molecular targets have been identified for adenocarcinoma (ACA) of the lung, similar drivers with squamous cell carcinoma (SCC) are sparse. We compared signaling pathways and potential therapeutic targets in lung SCC and ACA tumors using reverse phase proteomic arrays (RPPA) from two independent cohorts of resected early stage NSCLC patients: a testing set using an MDACC cohort (N=140) and a validation set using the Cancer Genome Atlas (TCGA) cohorts. We identified multiple… CONTINUE READING